Indices of Effectiveness of Treatment

  • Lawrence R. Freedman
Part of the Current Topics in Infectious Disease book series (CTID)

Abstract

Evidence of clinical improvement after the institution of effective antibiotic treatment is usually not dramatic. Patients may have prompt normalization of temperature, in which case they might feel very much better quickly. On the other hand, although fever usually does subside within 2–4 days, this subsidence is gradual, and dramatic response is not the rule. Persistence of fever may indicate ineffective antibiotic therapy or a drug reaction. In some patients, persistent low-grade fever will continue as long as the patient receives antibiotics. Reappearance of fever after an afebrile interval may indicate embolization (pulmonary or arterial), infectious complications of prolonged intravenous therapy, reseeding of the bloodstream from a peripheral abscess, or drug reaction. Rarely, persistence of fever may be an indication of the presence of concomitant underlying disease such as lymphoma or myxoma.

Keywords

Toxicity Hepatitis Lymphoma Anemia Penicillin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lingeman, C. J., Smith, E. B., Battersby, J. S., Behnke, R. H.: Subacute bacterial endocarditis—Splenectomy in cases refractory to antibiotic therapy. Arch. Intern. Med. 97: 309–314, 1956.CrossRefGoogle Scholar
  2. 2.
    Godeau, P., Wechsler, B., Heffernan, G., Balafrej, M., Bletry, O., Squalli, S.: Rupture de rate au cours des endocardites bactériennes: 2 observations. Nouv. Presse Med. 8: 2811–2814, 1979.PubMedGoogle Scholar
  3. 3.
    Gonin, A., Berthou, J. D., Simonin, C., Delaye, J. C., Roques, J. C., Dufoix, V.: Ruptures spontanées de rate au cours de l’endocardite infectieuse—A propos de 3 nouvelles observations. Lyon Med. 229 (12): 1269–1271, 1973.Google Scholar
  4. 4.
    Durack, D. T., Beeson, P. B.: Protective role of complement in experimental Escherichia coli endocarditis. Infect. Immun. 16: 213–217, 1977.PubMedGoogle Scholar
  5. 5.
    Archer G., Fekety, F. R., Jr.: Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model. J. Infect. Dis. 134: 1–7, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaspar, R. L., Drutz, D. J.: Perihepatitis and hepatitis as complications of experimental endocarditis due to Neisseria gonorrhoeae in the rabbit. J. Infect. Dis. 136: 37–42, 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Alexander, W. J., Curtiss, R., III, Bradac, J. A., Cobbs, C. G.: Rifampin modifies serum susceptibility of E. coli and its virulence in rabbit endocarditis model (abstract). Clin. Res. 26: 26A, 1978.Google Scholar
  8. 8.
    Pulliam, L., Inokuchi, S., Hadley, W. K., Mills, J.: Penicillin tolerance in experimental streptococcal endocarditis. Lancet 2: 957, 1979.PubMedCrossRefGoogle Scholar
  9. 9.
    Carrizosa, J., Kaye, D.: Antibiotic concentrations in serum, serum bactericidal activity, and results of therapy of streptococal endocarditis in rabbits. Antimicrob. Agents Chemother. 12: 479–483, 1977.PubMedGoogle Scholar
  10. 10.
    Egert, J., Carrizosa, J., Kaye, D.: Comparison of methicillin, nafcillin, and oxacillin in therapy of Staphylococcus aureus endocarditis in rabbits. J. Lab. Clin. Med. 89: 1262–1268, 1977.PubMedGoogle Scholar
  11. 11.
    Carrizosa, J., Santoro, J., Kaye, D.: Treatment of experimental Staphylococcus aureus endocarditis: Comparison of cephalothin, cefazolin, and methicillin. Antimicrob. Agents Chemother. 13: 74–77, 1978.PubMedGoogle Scholar
  12. 12.
    Reyes, M. P., Riad El-Khatib, M., Brown, W. J., Smith, F., Lerner, A. M.: Synergy between carbenicillin and an aminoglyocoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J. Infect. Dis. 140: 192–202, 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Reyes, M. P., Brown, W. J., Lerner, A. M.: Treatment of patients with Pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. Medicine 57: 57–67, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Bryan, C. S., Marney, S. R., Alford, R. H., Bryant, R. E.: Gram-negative bacillary endocarditis. Am. J. Med. 58: 209–215, 1975.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Keate, J. P., Gorbach, S. L.: Laboratory diagnosis of infective endocarditis, in: Infective Endocarditis, Rahintoola, S. H., Ed. Grune and Stratton, New York, pp. 307–325, 1978.Google Scholar
  16. 16.
    Bryant, R. E., Kimbrough, R. C.: Treatment of infective endocarditis, in: Infective Endocarditis, Rahintoola, S. H., Ed. Grune and Stratton, New York, pp. 327–360, 1978.Google Scholar
  17. 17.
    Pien, F. D., Williams, R. D., Vosti, K. L.: Comparison of broth and human serum as the diluent in the serum bactericidal test. Antimicrob. Agents Chemother. 7: 113–114, 1975.PubMedGoogle Scholar
  18. 18.
    Stratton, C. W., Relier, L. B.: Serum dilution test for bactericidal activity. I. Selection of a physiology diluent. J. Infect. Dis. 136: 187–195, 1977.PubMedCrossRefGoogle Scholar
  19. 19.
    Relier, L. B., Stratton, C. W.: Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobials assays and susceptibility tests. J. Infect. Dis. 136: 196–204, 1977.CrossRefGoogle Scholar
  20. 20.
    McLoed, R., Remington, J. S.: Fungal endocarditis, in: Infective Endocarditis, Rahimtoola, S.H., Ed. Grune and Stratton, New York, pp. 211–290, 1978.Google Scholar
  21. 21.
    Seeling, M. S., Golberg, P., Kozinn, P. J., Berger. A. R.: Fungal endocarditis: Patients at risk and their treatment. Postgrad. Med. J. 55: 632–641, 1979.CrossRefGoogle Scholar
  22. 22.
    Bastin, R., Vilde, J. L., Frottier, J., Lejeune, A.: La chirurgie cardiaque dans les endocardites a la periode infectieuse Coeur No. Special: Journées internationales de cardiologie conascrées aux remplacements valvulaires, Oct. 1974, Deauville.Google Scholar
  23. 23.
    Stinson, E. B., Griepp, R. B., Vosti, K., Copeland, J. G., Shumway, N. E.: Operative treatment of active endocarditis. J. Thorac. Cardiovasc. Surg. 71: 659–665, 1976.PubMedGoogle Scholar
  24. 24.
    Stinson, E. B.: Surgical treatment of infective endocarditis. Prog. Cardiovasc. Dis. 22:145–168, 1979.Google Scholar
  25. 25.
    Olsen, E. G. J.: Endomyocardial fibrosis and Löffler’s endocarditis parietalis fibroplastica. Postgrad. Med. J. 53: 538–540, 1977.PubMedCrossRefGoogle Scholar
  26. 26.
    Boyd, A. D., Spencer, F. C., Isom, O. W., Cunningham, J. N., Reed, G. E., Acinapura, A. J., Tice, D. A.: Infective endocarditis—An analysis of 54 surgically treated patients. J. Thorac. Cardiovasc. Surg. 73: 23–30, 1977.PubMedGoogle Scholar
  27. 27.
    Christol, D., Witchitz, S., Duval, J., Guyonnaud, C. D., Bouton, C., Garnier, I.: Etude anatomique et bactériologique des pièces de valvulectomie chez les malades ayant une endocardite bactérienne. Nouv. Presse Med. 6: 1355–1358, 1977.PubMedGoogle Scholar
  28. 28.
    Freedman, L. R., Johnson, M. L.: Experimental endocarditis. IV. Tricuspid and aortic value infection with Candida albicans in rabbits. Yale J. Biol. Med. 45: 163–175, 1972.PubMedGoogle Scholar
  29. 29.
    Badger, S. J., Butler, T., Kim, C. K., Johnston, K. H.: Experimental Eikenella corrodens endocarditis in rabbits. Infect. Immun. 23: 751–757, 1978.Google Scholar
  30. 30.
    McGowan, D. A.: Scanning electron microscopy of heart-valve vegetations. Lancet 2: 822, 1977.PubMedCrossRefGoogle Scholar
  31. 31.
    Mackowiak, P. A., Cohen, R. L.: The effect of physiological hyperthermia on minimal inhibitory concentrations (MICs). 20th ICAAC, Sept. 1980, Abstract 399.Google Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • Lawrence R. Freedman
    • 1
  1. 1.VA Wadsworth Medical CenterUCLA School of MedicineLos AngelesUSA

Personalised recommendations